Related Experiment Video
Updated: Mar 21, 2026

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
Effects of Diactive-1-Supported Progressive Resistance Training on Body Composition in Youth With Type 1 Diabetes
Jacinto Muñoz-Pardeza1, José Francisco López-Gil2,3, Ignacio Hormazábal-Aguayo1,4
1Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.
Background:
Compared to their healthy peers, children and adolescents with type 1 diabetes are at an increased risk of adverse changes in body composition, including increased fat mass along with reductions in lean and bone mass. Although exercise has shown promise in improving body mass index in this population, the individual effects of resistance training on specific body composition parameters remain understudied. The aim of the study was to evaluate the effects of resistance training supported by the mHealth application Diactive-1 on body composition in children and adolescents with type 1 diabetes.
Methods:
Sixty-two participants with type 1 diabetes (aged 8-18 years old; 48% females) participated in a 24-week randomised controlled trial and were assigned to either the usual care group (n = 32) or the exercise group (n = 30). The intervention was delivered via the Diactive-1 app, which generates progressive overload resistance training programmes tailored to real-time glycaemia and provides educational support. Body composition was assessed using anthropometry and dual-energy X-ray absorptiometry, with fat, lean and bone measurements standardised by age, sex and ethnicity. Linear mixed models were used to evaluate between-group differences in change over time under both intention-to-treat (ITT) and per-protocol (PP) approaches.
Results:
At 24 weeks, in the ITT analysis, the intervention group showed greater gains in lean mass (mean difference [MD] = 0.88 kg; 95% confidence interval [CI] 0.09 to 1.66; Hedges' g = 0.568) and whole-body bone mineral content less head (MD = 32.40 g; 95% CI 6.90 to 57.89; g = 0.644) compared with those in the usual care group. No changes were observed in anthropometric measures, fat mass-related regions or standardised variables (p > 0.05). The risk of probable sarcopenia was lower in the intervention group (relative risk [RR] = 0.17; 95% CI 0.04 to 0.73; Cohen's h = 0.987) than in the usual care group. Findings were directionally consistent in the PP analysis.
Conclusions:
This intervention increased bone-related outcomes and was associated with modest gains in lean mass and a lower risk of probable sarcopenia in youths with type 1 diabetes. These findings highlight the potential of the Diactive-1 app as an adjunct tool to support musculoskeletal health in youths with type 1 diabetes.
Trial Registration:
ClinicalTrials.gov identifier: NCT06048757.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Exercise and Muscle Performance
Endurance exercises
Endurance exercises involve running, swimming, or cycling, which require repetitive movements with low force output. When a person engages in endurance exercise, a few noticeable changes occur in their skeletal muscles. For instance, the number of capillaries...
Diabetes Mellitus: Type 2 and Gestational
Drug Dosing: Obese Patients

